- Motley Fool•2 days ago
A patent review board rules that claims on Teva Pharmaceuticals' three-times-weekly version of Copaxone aren't patentable.
- Benzinga•2 days ago
Argus maintained its Hold rating on Novartis AG (ADR) (NYSE: NVS ) as it looks for a favorable entry point. However, the brokerage's long-term rating on the stock is Buy as many of the drugs under development ...
- Zacks•2 days ago
Novartis AG (NVS) entered into a license agreement with privately held Cyon Therapeutics Inc. for its anti-PCSK9 antibody, LGT-209.
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||79.37 x 2100|
|Ask||79.43 x 4400|
|Day's Range||79.44 - 80.11|
|52wk Range||69.90 - 98.95|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.40|
|Avg Vol (3m)||1,478,465|
|Dividend & Yield||2.72 (3.38%)|